Novartis has presented new data that demonstrated once-daily Ultibro Breezhaler (indacaterol/glycopyrronium bromide) was superior in reducing exacerbations (flare ups) and...
Novartis has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...
Novartis has announced the New England Journal of Medicine publication of the head-to-head FLAME study comparing the efficacy of once-daily...
New analyses from the head-to-head FLAME study confirmed that Ultibro Breezhaler (indacaterol/glycopyrronium bromide), from Novartis, is a more effective option...
Novartis announced new data from the QUANTIFY study, which demonstrated the non-inferiority of Ultibro Breezhaler (indacaterol/glycopyrronium) 110/50 mcg compared to...
Novartis has announced that the European Commission approved once-daily Ultibro Breezhaler (indacaterol 85 mcg / glycopyrronium 43 mcg) as a...
Novartis has announced positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating patients...
Novartis has filed a new drug application (NDA) for QVA 149 (indacaterol/glycopyrronium bromide) to treat Chronic Obstructive Pulmonary Disease (COPD)...
Novartis announced the publication of the CLAIM study in the Lancet Respiratory Medicine, which demonstrated that treatment once-daily Ultibro Breezhaler...
Novartis announced new analyses of data for once-daily Ultibro Breezhaler (investigational QVA 149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered...